Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

The global preclinical antibacterial pipeline.

Theuretzbacher U, Outterson K, Engel A, Karlén A.

Nat Rev Microbiol. 2019 Nov 19. doi: 10.1038/s41579-019-0288-0. [Epub ahead of print] Review.

PMID:
31745331
2.

The small-molecule antibiotics pipeline: 2014-2018.

Lepore C, Silver L, Theuretzbacher U, Thomas J, Visi D.

Nat Rev Drug Discov. 2019 Sep;18(10):739. doi: 10.1038/d41573-019-00130-8. No abstract available.

PMID:
31570838
3.

Non-traditional Antibacterial Therapeutic Options and Challenges.

Theuretzbacher U, Piddock LJV.

Cell Host Microbe. 2019 Jul 10;26(1):61-72. doi: 10.1016/j.chom.2019.06.004. Review.

PMID:
31295426
4.

Analysis of the clinical antibacterial and antituberculosis pipeline.

Theuretzbacher U, Gottwalt S, Beyer P, Butler M, Czaplewski L, Lienhardt C, Moja L, Paul M, Paulin S, Rex JH, Silver LL, Spigelman M, Thwaites GE, Paccaud JP, Harbarth S.

Lancet Infect Dis. 2019 Feb;19(2):e40-e50. doi: 10.1016/S1473-3099(18)30513-9. Epub 2018 Oct 15. Review.

PMID:
30337260
5.

Developing a new antibiotic for extensively drug-resistant pathogens: the case of plazomicin.

Theuretzbacher U, Paul M.

Clin Microbiol Infect. 2018 Dec;24(12):1231-1233. doi: 10.1016/j.cmi.2018.07.020. Epub 2018 Aug 1. No abstract available.

PMID:
30076976
6.

Concentration-dependent plasma protein binding: Expect the unexpected.

Nation RL, Theuretzbacher U, Tsuji BT; International Society of Anti-Infective Pharmacology (ISAP).

Eur J Pharm Sci. 2018 Sep 15;122:341-346. doi: 10.1016/j.ejps.2018.07.004. Epub 2018 Jul 3. Review.

PMID:
30026170
7.

Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial.

Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S.

JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627.

8.

Colistin versus colistin plus meropenem for severe infections Authors' reply.

Paul M, Carmeli Y, Daikos GL, Durante-Mangoni E, Theuretzbacher U, Mouton JW, Leibovici L.

Lancet Infect Dis. 2018 May;18(5):495-496. doi: 10.1016/S1473-3099(18)30223-8. No abstract available.

PMID:
29695358
9.

Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations.

Årdal C, Baraldi E, Theuretzbacher U, Outterson K, Plahte J, Ciabuschi F, Røttingen JA.

J Pharm Policy Pract. 2018 Apr 5;11:8. doi: 10.1186/s40545-018-0135-0. eCollection 2018.

10.

Unavailability of old antibiotics threatens effective treatment for common bacterial infections.

Tängdén T, Pulcini C, Aagaard H, Balasegaram M, Hara GL, Nathwani D, Sharland M, Theuretzbacher U, Cars O.

Lancet Infect Dis. 2018 Mar;18(3):242-244. doi: 10.1016/S1473-3099(18)30075-6. No abstract available. Erratum in: Lancet Infect Dis. 2018 Feb 28;:.

PMID:
29485082
11.

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.

Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.

PMID:
29456043
12.

Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.

Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N; WHO Pathogens Priority List Working Group.

Lancet Infect Dis. 2018 Mar;18(3):318-327. doi: 10.1016/S1473-3099(17)30753-3. Epub 2017 Dec 21.

PMID:
29276051
13.

Global antimicrobial resistance in Gram-negative pathogens and clinical need.

Theuretzbacher U.

Curr Opin Microbiol. 2017 Oct;39:106-112. doi: 10.1016/j.mib.2017.10.028. Epub 2017 Nov 15. Review.

PMID:
29154024
14.

β-lactam prolonged infusion: it's time to implement!

Paul M, Theuretzbacher U.

Lancet Infect Dis. 2018 Jan;18(1):13-14. doi: 10.1016/S1473-3099(17)30614-X. Epub 2017 Nov 5. No abstract available.

PMID:
29102323
15.

Market watch: Innovation in the preclinical antibiotic pipeline.

Theuretzbacher U, Savic M, Årdal C, Outterson K.

Nat Rev Drug Discov. 2017 Nov;16(11):744-745. doi: 10.1038/nrd.2017.195. Epub 2017 Oct 6. No abstract available.

PMID:
28983100
16.

New drugs - will they solve the problem of resistance to antibiotics?

Theuretzbacher U.

Clin Microbiol Infect. 2017 Oct;23(10):695-696. doi: 10.1016/j.cmi.2017.08.013. Epub 2017 Aug 19. No abstract available.

17.

Antibiotic innovation for future public health needs.

Theuretzbacher U.

Clin Microbiol Infect. 2017 Oct;23(10):713-717. doi: 10.1016/j.cmi.2017.06.020. Epub 2017 Jun 24. Review.

18.

Linking Sustainable Use Policies to Novel Economic Incentives to Stimulate Antibiotic Research and Development.

Theuretzbacher U, Årdal C, Harbarth S.

Infect Dis Rep. 2017 Mar 30;9(1):6836. doi: 10.4081/idr.2017.6836. eCollection 2017 Mar 30. Review.

19.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
20.

Erratum to 'Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia': [International Journal of Antimicrobial Agents 49/1 (2017) 98-101].

Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP); ReAct Working Group on Old Antibiotics.

Int J Antimicrob Agents. 2017 Apr;49(4):482. doi: 10.1016/j.ijantimicag.2017.02.006. Epub 2017 Mar 3. No abstract available.

PMID:
28264779
21.

Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia.

Pulcini C, Mohrs S, Beovic B, Gyssens I, Theuretzbacher U, Cars O; ESCMID Study Group for Antibiotic Policies (ESGAP), ReAct Working Group on Old Antibiotics.

Int J Antimicrob Agents. 2017 Jan;49(1):98-101. doi: 10.1016/j.ijantimicag.2016.09.029. Epub 2016 Nov 16. Erratum in: Int J Antimicrob Agents. 2017 Apr;49(4):482.

PMID:
27887966
22.

Market watch: Antibacterial innovation in European SMEs.

Theuretzbacher U.

Nat Rev Drug Discov. 2016 Dec;15(12):812-813. doi: 10.1038/nrd.2016.229. Epub 2016 Nov 18. No abstract available.

PMID:
27857138
23.

Closing the evidence gap in infectious disease: point-of-care randomization and informed consent.

Huttner A, Leibovici L, Theuretzbacher U, Huttner B, Paul M.

Clin Microbiol Infect. 2017 Feb;23(2):73-77. doi: 10.1016/j.cmi.2016.07.029. Epub 2016 Aug 3. Review.

24.

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.

Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium.

BMJ Open. 2016 Apr 20;6(4):e009956. doi: 10.1136/bmjopen-2015-009956.

25.

Revival of old antibiotics: structuring the re-development process to optimize usage.

Theuretzbacher U, Paul M.

Clin Microbiol Infect. 2015 Oct;21(10):878-80. doi: 10.1016/j.cmi.2015.06.019. Epub 2015 Jun 25. No abstract available.

26.

Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective.

Muller AE, Theuretzbacher U, Mouton JW.

Clin Microbiol Infect. 2015 Oct;21(10):881-5. doi: 10.1016/j.cmi.2015.06.007. Epub 2015 Jun 17. Review.

27.

Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials.

Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW.

J Antimicrob Chemother. 2015 Sep;70(9):2456-64. doi: 10.1093/jac/dkv147. Epub 2015 Jun 11. Review.

PMID:
26066581
28.

Reviving old antibiotics.

Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, Turnidge JD, Kahlmeter G.

J Antimicrob Chemother. 2015 Aug;70(8):2177-81. doi: 10.1093/jac/dkv157. Epub 2015 Jun 10. Review.

PMID:
26063727
29.

In memoriam: William A. Craig.

Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL.

Antimicrob Agents Chemother. 2015;59(6):2971. doi: 10.1128/AAC.00849-15. Epub 2015 Apr 20. No abstract available.

30.

Antibiotic research and development: business as usual?

Harbarth S, Theuretzbacher U, Hackett J; DRIVE-AB consortium.

J Antimicrob Chemother. 2015;70(6):1604-7. doi: 10.1093/jac/dkv020. Epub 2015 Feb 10.

PMID:
25673635
31.

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Lancet Infect Dis. 2015 Feb;15(2):225-34. doi: 10.1016/S1473-3099(14)70850-3. Epub 2014 Oct 21.

PMID:
25459221
32.

Combination therapy for carbapenem-resistant Gram-negative bacteria.

Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L.

J Antimicrob Chemother. 2014 Sep;69(9):2305-9. doi: 10.1093/jac/dku168. Epub 2014 May 28. Review.

PMID:
24872346
33.

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases.

Lancet Infect Dis. 2014 Jun;14(6):498-509. doi: 10.1016/S1473-3099(14)70036-2. Epub 2014 Apr 24. Review.

34.

Impact of availability of guidelines and active surveillance in reducing the incidence of ventilator-associated pneumonia in Europe and worldwide.

Kaier K, Lambert ML, Frank UK, Vach W, Wolkewitz M, Tacconelli E, Rello J, Theuretzbacher U, Martin M.

BMC Infect Dis. 2014 Apr 12;14:199. doi: 10.1186/1471-2334-14-199.

35.

Product information for parenteral colistin varies substantially across Europe.

Theuretzbacher U.

J Antimicrob Chemother. 2014 Jul;69(7):1987-92. doi: 10.1093/jac/dku064. Epub 2014 Mar 14.

PMID:
24633204
36.

Consistent global approach on reporting of colistin doses to promote safe and effective use.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Clin Infect Dis. 2014 Jan;58(1):139-41. doi: 10.1093/cid/cit680. Epub 2013 Oct 8. No abstract available.

PMID:
24107410
37.

Treatment of extensively drug-resistant Gram-negative infections in critically ill patients: Outcome of a consensus meeting at the 13th Asia-Pacific Congress of Clinical Microbiology and Infection, October 2012.

Tambyah PA, Hara GL, Daikos GL, Falagas ME, Mazzei T, Mouton JW, Novelli A, Chen B, Wang M, Ko WC, Li T, Fan X, Theuretzbacher U.

J Glob Antimicrob Resist. 2013 Sep;1(3):117-122. doi: 10.1016/j.jgar.2013.04.002. Epub 2013 May 23. Review.

PMID:
27873621
38.

Global antibacterial resistance: The never-ending story.

Theuretzbacher U.

J Glob Antimicrob Resist. 2013 Jun;1(2):63-69. doi: 10.1016/j.jgar.2013.03.010. Epub 2013 Apr 30. Review.

PMID:
27873580
39.

Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer.

Theuretzbacher U.

Clin Infect Dis. 2012 Jun;54(12):1785-92. doi: 10.1093/cid/cis210. Epub 2012 Mar 20. Review.

PMID:
22437238
40.

Accelerating resistance, inadequate antibacterial drug pipelines and international responses.

Theuretzbacher U.

Int J Antimicrob Agents. 2012 Apr;39(4):295-9. doi: 10.1016/j.ijantimicag.2011.12.006. Epub 2012 Feb 14. Review.

PMID:
22341298
41.

Update on antibacterial and antifungal drugs - can we master the resistance crisis?

Theuretzbacher U, Mouton JW.

Curr Opin Pharmacol. 2011 Oct;11(5):429-32. doi: 10.1016/j.coph.2011.08.002. Epub 2011 Sep 6. No abstract available.

PMID:
21903474
42.

Resistance drives antibacterial drug development.

Theuretzbacher U.

Curr Opin Pharmacol. 2011 Oct;11(5):433-8. doi: 10.1016/j.coph.2011.07.008. Epub 2011 Aug 19. Review.

PMID:
21862408
43.

The effect of critical illness on drug distribution.

Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H.

Curr Pharm Biotechnol. 2011 Dec;12(12):2030-6. Review.

PMID:
21554214
44.

Protein binding: do we ever learn?

Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U.

Antimicrob Agents Chemother. 2011 Jul;55(7):3067-74. doi: 10.1128/AAC.01433-10. Epub 2011 May 2. Review.

45.

Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective.

Mouton JW, Ambrose PG, Canton R, Drusano GL, Harbarth S, MacGowan A, Theuretzbacher U, Turnidge J.

Drug Resist Updat. 2011 Apr;14(2):107-17. doi: 10.1016/j.drup.2011.02.005. Epub 2011 Mar 26. Review.

PMID:
21440486
46.

Pharmacokinetic/pharmacodynamic profile of posaconazole.

Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H.

Clin Pharmacokinet. 2010 Jun;49(6):379-96. doi: 10.2165/11319340-000000000-00000. Review.

PMID:
20481649
47.

Antibiotics: derivative drugs, novel compounds and the need for effective resistance strategies.

Theuretzbacher U.

Future Microbiol. 2009 Dec;4(10):1243-7. doi: 10.2217/fmb.09.97.

PMID:
19995184
48.

Future antibiotics scenarios: is the tide starting to turn?

Theuretzbacher U.

Int J Antimicrob Agents. 2009 Jul;34(1):15-20. doi: 10.1016/j.ijantimicag.2009.02.005. Epub 2009 Apr 1. Review.

PMID:
19342202
49.

Tissue concentrations: do we ever learn?

Mouton JW, Theuretzbacher U, Craig WA, Tulkens PM, Derendorf H, Cars O.

J Antimicrob Chemother. 2008 Feb;61(2):235-7. Epub 2007 Dec 6. Review.

PMID:
18065413
50.

Tissue penetration of antibacterial agents: how should this be incorporated into pharmacodynamic analyses?

Theuretzbacher U.

Curr Opin Pharmacol. 2007 Oct;7(5):498-504. Epub 2007 Jul 5. Review.

PMID:
17616438

Supplemental Content

Loading ...
Support Center